298 related articles for article (PubMed ID: 27007241)
21. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
[TBL] [Abstract][Full Text] [Related]
22. Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1376-1387. PubMed ID: 32653227
[TBL] [Abstract][Full Text] [Related]
23. Single-Agent Therapies After Standard Combination Regimens.
Chokshi S; Hochster HS
Cancer J; 2016; 22(3):205-10. PubMed ID: 27341600
[TBL] [Abstract][Full Text] [Related]
24. Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer.
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G; Miyakita H
Oncol Lett; 2018 Nov; 16(5):6589-6597. PubMed ID: 30344762
[TBL] [Abstract][Full Text] [Related]
25. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
26. TAS-102 for the treatment of metastatic colorectal cancer.
Salvatore L; Rossini D; Moretto R; Cremolini C; Schirripa M; Antoniotti C; Marmorino F; Loupakis F; Falcone A; Masi G
Expert Rev Anticancer Ther; 2015; 15(11):1283-92. PubMed ID: 26509228
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R
Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414
[TBL] [Abstract][Full Text] [Related]
28. Maximising clinical benefit with adequate patient management beyond the second line in mCRC.
Argiles G; Arnold D; Prager G; Sobrero AF; Van Cutsem E
ESMO Open; 2019; 4(2):e000495. PubMed ID: 31231561
[TBL] [Abstract][Full Text] [Related]
29. Different Toxicity Profiles Predict Third Line Treatment Efficacy in Metastatic Colorectal Cancer Patients.
Unseld M; Fischöder S; Jachs M; Drimmel M; Siebenhüner A; Bianconi D; Kieler M; Puhr H; Minichsdorfer C; Winder T; Prager GW
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32517383
[TBL] [Abstract][Full Text] [Related]
30. Treatment sequencing in metastatic colorectal cancer.
Modest DP; Pant S; Sartore-Bianchi A
Eur J Cancer; 2019 Mar; 109():70-83. PubMed ID: 30690295
[TBL] [Abstract][Full Text] [Related]
31. Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.
Burness CB; Duggan ST
Drugs; 2016 Sep; 76(14):1393-402. PubMed ID: 27568360
[TBL] [Abstract][Full Text] [Related]
32. The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program-Results of a Survey on Daily Practice Patterns for Patients with mCRC.
Prager G; Köhne CH; O'Connor JM; Rivera F; Santini D; Wasan H; Phelip JM
Curr Oncol; 2021 Jun; 28(3):2097-2106. PubMed ID: 34199694
[TBL] [Abstract][Full Text] [Related]
33. Metastatic Colorectal Cancer: Management With Trifluridine/Tipiracil
.
White T; Larson H; Minnella A; Hochster HS
Clin J Oncol Nurs; 2017 Apr; 21(2):E30-E37. PubMed ID: 28315543
[TBL] [Abstract][Full Text] [Related]
34. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion.
Fernández-Montes A; Grávalos C; Pericay C; Safont MJ; Benavides M; Élez E; García-Alfonso P; García-Paredes B; Carrato A; Aranda E
Clin Colorectal Cancer; 2020 Sep; 19(3):165-177. PubMed ID: 32507561
[TBL] [Abstract][Full Text] [Related]
35. Regorafenib and trifluridine/tipiracil in real clinical practice.
García-Beloso N; Romero-Ventosa EY; Gayoso-Rey M; López-López A; Robles-Torres D; de Castro NM; Piñeiro-Corrales G
J Cancer Res Ther; 2022 Dec; 18(Supplement):S367-S373. PubMed ID: 36510990
[TBL] [Abstract][Full Text] [Related]
36. Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study.
Signorelli C; Calegari MA; Basso M; Anghelone A; Lucchetti J; Minelli A; Angotti L; Zurlo IV; Schirripa M; Chilelli MG; Morelli C; Dell'Aquila E; Cosimati A; Gemma D; Ribelli M; Emiliani A; Corsi DC; Arrivi G; Mazzuca F; Zoratto F; Morandi MG; Santamaria F; Saltarelli R; Ruggeri EM
Curr Oncol; 2023 Jun; 30(6):5456-5469. PubMed ID: 37366896
[TBL] [Abstract][Full Text] [Related]
37. [Regorafenib and Trifluridine and Tipiracil Hydrochloride Can Potentially Improve the Survival Time for Patients with Advanced or Recurrent Colorectal Cancer].
Oki M; Nakamura A; Shinamura N; Sugaya T; Takagi K; Sugaya M
Gan To Kagaku Ryoho; 2018 Sep; 45(9):1297-1303. PubMed ID: 30237371
[TBL] [Abstract][Full Text] [Related]
38. Emerging combination therapies for metastatic colorectal cancer - impact of trifluridine/tipiracil.
Puthiamadathil JM; Weinberg BA
Cancer Manag Res; 2017; 9():461-469. PubMed ID: 29056855
[TBL] [Abstract][Full Text] [Related]
39. Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer.
Kimura M; Usami E; Iwai M; Go M; Teramachi H; Yoshimura T
Mol Clin Oncol; 2016 Nov; 5(5):635-640. PubMed ID: 27900102
[TBL] [Abstract][Full Text] [Related]
40. Trifluridine/tipiracil for the treatment of metastatic gastric cancer.
Kawazoe A; Shitara K
Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):65-70. PubMed ID: 31920125
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
